Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2023 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are themselves doing and scaling. The key is whether management's forward account is substantially about the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories. Let's examine the transcript. Management discusses several channels: rental (prescriber channel), B2B (domestic and international), DTC, and new product launches. They mention progress in rental revenue, adding private payers, B2B dynamics, international reimbursements, etc. But do they narrate specific counterparties' own scaling? For example, they mention "we recently added two large private health care payers" and "we now can cover the COPD patient population out of approximately 160 million privately-covered lives." That is about coverage, not about those payers' own expansion. They mention "we have made solid progress after launching Rove 6 in Europe" and "granted reimbursement in Germany" and "received confirmation of Rove 6 coverage in France" – that's about regulatory approvals, not about counterparties scaling. They talk about HME partners: "some of the larger HMEs have increased their focus on margin accretion, restructuring and capital expense management." That is describing challenges, not their growth. They say "our strong and unique value proposition remains solid... This has helped in adding new HME customers and expanding the base we serve while we manage competitive pressures." That is about their own efforts to add customers, not about those customers' own trajectories. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? The essence is that management reports on somebody else's growth as the reason for its own, and speaks about that other party's plans with familiarity. Here, management does not describe specific counterparties' own ramps, launches, rollouts, capacity additions, etc. They mention adding payers, but that's about coverage, not about payers' own expansion.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.